Antiplatelet and Anticoagulation Therapy In PCI, An Issue of Interventional Cardiology Clinics, 1st Edition
Author :
By Dominick J. Angiolillo, MD, PhD and Matthew J. Price, MD
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet ag
...view more
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.
Author Information
By Dominick J. Angiolillo, MD, PhD, University of Florida College of Medicine-Jacksonville and Matthew J. Price, MD, Scripps Clinic, La Jolla CA
https://www.asia.elsevierhealth.com/antiplatelet-and-anticoagulation-therapy-in-pci-an-issue-of-interventional-cardiology-clinics-9780323482622.html295060Antiplatelet and Anticoagulation Therapy In PCI, An Issue of Interventional Cardiology Clinicshttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9780323482622_8.jpg62.0968.99USDInStock/Clinics/Medicine & Surgery/Cardiology/Medicine/Cardiology/Clinics/Clinics/Medicine/Cardiology/Japan Titles43887254431212505456950546665255041525985052631601418269243350884886536505455351451205259833This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics. This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.00add-to-cart97803234826222016ProfessionalBy Dominick J. Angiolillo, MD, PhD and Matthew J. Price, MD20171Book178w x 254h (7.00" x 10.00")Elsevier0Dec 6, 2016IN STOCKBy <STRONG>Dominick J. Angiolillo</STRONG>, MD, PhD, University of Florida College of Medicine-Jacksonville and <STRONG>Matthew J. Price</STRONG>, MD, Scripps Clinic, La Jolla CAClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
